Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Sun Phar 483.40 2.16
Power Gr 171.45 3.94
Bajaj Au 2860.00 2.30
H D F C 1105.00 10.40
Hind Uni 2178.00 3.36
Clear All Clear Last
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
FII Activity
Mutual Fund Activity
Results Watch
Results Calendar
Results Announced
IPO Watch
Recent News
Broker Research
Research Tutorial
Discussion Forum
Research Reports
Sector Watch
Economy Watch
Krebs Biochemicals & Industries Limited
Sector:Chemicals Chemicals - Chemicals - Others
Market Lot: 1Face Value: 10ISIN Demat: INE268B01013
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

Business Profile
Krebs Biochemicals & Industries (KREBSBIO) is engaged in the manufacture of bulk actives, intermediates, active pharmaceutical ingredients (API) and other products. Established in 1991 as a public limited company, the company was earlier known as Krebs Biochemicals and got its present name on Dec. 10, 2003.

The ISO 9001:2000 certified company manufactures Ephedrine HCL, Pseudoephedrine HCL, Lovastatin, Sucralose, Simvastatin, Vitamin-C and other products. It also manufactures sugar and potato chips. The manufacturing units have certification from US FDA and EDQM and total five in number. They are located in the Nellore and Guntur districts, Hyderabad and Visakhapatnam in Andhra Pradesh. A 2.5 MW co-generation power plant has been set up at unit II to meet the in-house steam and power requirements of the process plant.

In FY07, the company entered into a manufacturing agreement with Ranbaxy Laboratories for undertaking a series of exhibit batches for new high value products at its Nellore plant and successfully completed two product campaigns. In January 2008, it signed a manufacturing contract with Germany`s Wacker Chemie AG and also signed a preliminary agreement with it to form a joint venture for the manufacture of various products. The company would hold 49% stake in the joint venture. A co-marketing agreement is in place with Ranbaxy Laboratories to market Lovastatin and Simvastatin in new European and other markets. Tie-ups with major distribution firms in UK, Sri Lanka and India and tie-ups with other private label operations in India and Middle East will boost exports.

The registered office is located at 401/402, Cyber Heights, 4th Floor, Plot No-13, Road No.2, Banjara Hills, Hyderabad-500033, Andhra Pradesh.

The company disclosed rise of 257.41% in standalone net profit on y-o-y basis to Rs 74.66 million, while total income declined 72.58% y-o-y basis to Rs 11.13 million for the quarter ended June 2013.

Future Plans
Once the sugar unit of the company becomes operational, it would expand into many other organic products based on industrial biotechnology. The demand for bio fuels has enhanced importance of sugar industry. It will increase the turnover and profitability of the company substantially.

In Brief

Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited